Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Revenue: 2019-2025

Historic Revenue for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to $120.7 million.

  • BridgeBio Pharma's Revenue rose 4318.01% to $120.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $353.8 million, marking a year-over-year increase of 62.46%. This contributed to the annual value of $221.9 million for FY2024, which is 2285.27% up from last year.
  • BridgeBio Pharma's Revenue amounted to $120.7 million in Q3 2025, which was up 9.17% from $110.6 million recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's Revenue registered a high of $211.1 million during Q1 2024, and its lowest value of -$830,000 during Q4 2021.
  • Its 3-year average for Revenue is $52.6 million, with a median of $4.1 million in 2023.
  • Its Revenue has fluctuated over the past 5 years, first tumbled by 780.33% in 2021, then soared by 11,461.88% in 2024.
  • Over the past 5 years, BridgeBio Pharma's Revenue (Quarterly) stood at -$830,000 in 2021, then skyrocketed by 325.30% to $1.9 million in 2022, then dropped by 6.68% to $1.7 million in 2023, then surged by 237.08% to $5.9 million in 2024, then surged by 4,318.01% to $120.7 million in 2025.
  • Its Revenue was $120.7 million in Q3 2025, compared to $110.6 million in Q2 2025 and $116.6 million in Q1 2025.